A Q&A session was held at SCOPE 2024 in Orlando, Outsourcing Pharma speaks with Kelly McKee, VP of decentralized clinical trials and patient registries, and Daniel Braga, VP of EHR and healthcare solutions.
Meghan Harrington serves at Medidata as vice president of product, clinical trial financial management and is responsible for driving the strategic direction of the grants manager and payments products.
The company states that the new app is able to cut study start-up times for sponsors and CROs, while it can also be used by patients across various different platforms.
Integrated research organization Circuit Clinical will standardize its decentralized operations with Medidata’s RAVE and myMedidata technological offerings.
The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.
This month’s list of announcements about technology, funding, and more includes Medable, Clarify Health, Thermo Fisher Scientific, and other key companies.
The technology is designed to streamline and simplify integration, data collection and analysis, and digital biomarker discovery with wearable sensors.
Through organizations like the Association of Clinical Research Organizations, clinical research professionals are helping decentralized research evolve.
The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.
The company’s Medidata Detect centralized trial monitoring solution is designed to improve management of data quality, site monitoring and patient safety.
The companies will work together on putting in place technology to facilitate remote monitoring and document review for COVID-19 studies and other research.
The company’s global analysis from thousands of studies and sites indicates dramatic shifts in enrollment across several countries since the pandemic began.
Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
Strict timeframes set from sponsors in clinical studies often come in conflict with patients’ convenience, forming the biggest challenge to patient-centricity, says Medidata.
Dassault Systèmes’s $5.8bn acquisition of Medidata is complete – opening up ‘a new world of virtual twin experiences’ for health care, according to the French software firm.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
Medidata is building a global library of pre-configured, pre-approved eCOA questionnaires to accelerate study start-up in collaboration with Icon's Mapi Research Trust – “a win-win-win” for all involved.
Dassault Systèmes’ Living Heart Project is moving forward with an in silico clinical trial underway and plans to evaluate the use of virtual patients – as the French software company hopes to reduce costs, timelines, and improve quality across the industry,...
Phastar expands globally, adding offices in Japan and the US, and enters a partnership with Medidata to transform its increasing data points into insights.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Medidata is working with Cognizant to develop a set of services that will provide pharma, biotech, CROs and others with the capabilities to “digitally transform” their research and commercialization.
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
Medidata’s machine learning-based solution revealed novel biomarkers for Castleman disease among other discoveries that could help accelerate diagnosis and treatment.
Parexel is adopting Medidata’s Shyft Analytics platform to bolster its real-world evidence generation and outcomes research offering to biopharmaceutical and medical device clients.
In another sign that mobile health technology is beginning to take off, cloud-based solution provider Medidata is collaborating with Garmin to integrate its vívofit activity tracker with the Medidata Clinical Cloud.
Operating income at Medidata grew in the first quarter, underpinned by record bookings by contract research organisations (CRO) and rising revenues from Asia Pacific.
Medidata has followed its successful IPO by posting an operating profit in Q2, having made a loss last year, and giving a positive outlook for the rest of the year.
Medidata has launched a programme to encourage interoperability and data sharing across clinical trial technologies, which should help cope with the complexity of modern research.